6,434 Shares in Zoetis Inc (ZTS) Purchased by Lourd Capital LLC

6,434 Shares in Zoetis Inc (ZTS) Purchased by Lourd Capital LLC

Lourd Capital LLC purchased a new position in Zoetis Inc (NYSE:ZTS) in the third quarter, HoldingsChannel reports. The fund purchased 6,434 shares of the company’s stock, valued at approximately $589,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Valeo Financial Advisors LLC raised its holdings in shares of Zoetis by 34.4% during the second quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock valued at $202,000 after acquiring an additional 566 shares during the last quarter. Dupont Capital Management Corp raised its holdings in shares of Zoetis by 2.5% during the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock valued at $2,088,000 after acquiring an additional 601 shares during the last quarter. Dorsey Wright & Associates raised its holdings in shares of Zoetis by 7.9% during the second quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock valued at $714,000 after acquiring an additional 617 shares during the last quarter. Rehmann Capital Advisory Group raised its holdings in shares of Zoetis by 40.5% during the second quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock valued at $187,000 after acquiring an additional 631 shares during the last quarter. Finally, Wrapmanager Inc. raised its holdings in shares of Zoetis by 7.9% during the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock valued at $782,000 after acquiring an additional 672 shares during the last quarter. 89.76% of the stock is owned by institutional investors.

In related news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $92.03, for a total value of $184,060.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kristin C. Peck sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total value of $431,100.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 213,467 shares of company stock valued at $19,502,725. Insiders own 0.35% of the company’s stock.

NYSE:ZTS opened at $92.55 on Wednesday. Zoetis Inc has a one year low of $63.03 and a one year high of $94.31. The company has a quick ratio of 2.92, a current ratio of 4.38 and a debt-to-equity ratio of 2.50. The company has a market capitalization of $44.12 billion, a P/E ratio of 38.56, a P/E/G ratio of 1.74 and a beta of 1.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The firm had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. During the same quarter last year, the firm earned $0.53 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, equities research analysts anticipate that Zoetis Inc will post 3.07 earnings per share for the current year.

A number of brokerages have commented on ZTS. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $98.00 target price on Zoetis and gave the company a “buy” rating in a report on Friday, July 27th. BMO Capital Markets reissued a “hold” rating and set a $82.00 target price on shares of Zoetis in a report on Thursday, August 2nd. Stifel Nicolaus increased their target price on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Finally, Bank of America increased their target price on Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 30th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $91.73.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: Hedge Funds

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Related posts

Leave a Comment